Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers

NCT05919108 is registered in ClinicalTrials.gov with Vanderbilt-Ingram Cancer Center as lead sponsor.

NCT NCT05919108
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05919108 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
Lead sponsor
Vanderbilt-Ingram Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
June 11, 2024
Completion date
April 30, 2031
Enrollment
30 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage i breast cancer, anatomic stage ii breast cancer, anatomic stage iii breast cancer, invasive breast lobular carcinoma